- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01895985
Efficacy of Latanoprostene Bunod in Lowering Intraocular Pressure in Japanese Healthy Male Volunteers (KRONUS)
May 9, 2018 updated by: Bausch & Lomb Incorporated
A Single-Center, Open-Label Study Evaluating the Efficacy of Latanoprostene Bunod Ophthalmic Solution 0.024%, in Lowering Intraocular Pressure Over a 24-Hour Period in Japanese Healthy Male Volunteers
The objective of this study is to evaluate the effect of latanoprostene bunod dosed once daily (QD) in reducing intraocular pressure (IOP) measured over a 24-hour period in healthy subjects.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
24
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New Jersey
-
Madison, New Jersey, United States, 07940
- Bausch & Lomb Incorporated
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Participants with a corrected decimal visual acuity (VA) of 0.5 or better in both eyes.
Exclusion Criteria:
- Subjects with known hypersensitivity or contraindications to latanoprostene bunod, or any of the ingredients in the study drug.
- Subjects with known contraindications to NO treatment.
- Subjects who are unable to discontinue contact lens use at least 7 days prior to Visit 2 (Day 0/1/2) and during the 14 to 15-day study treatment period.
- Subjects who are unable to discontinue the use of all topical ophthalmic medications, including artificial tears, at least 7 days prior to Visit 2 (Day 0/1/2) and during the 14 to 15-day study treatment period.
- Subjects with any condition that prevents reliable applanation tonometry in either eye.
- Subjects with glaucoma in either eye.
- Subjects with any condition that prevents clear visualization of the fundus.
- Subjects who are monocular.
- Subjects with aphakia in either eye.
- Subjects with an active corneal disease in either eye.
- Subjects with severe dry eye in either eye.
- Subjects with a history/diagnosis of a clinically significant or progressive retinal disease in either eye.
- Subjects with any intraocular infection or inflammation within 3 months (90 days) prior to Visit 1 (Screening).
- Subjects with a history of ocular laser surgery within the 3 months (90 days) prior to Visit 1 (Screening).
- Subjects with a history of incisional ocular surgery or severe trauma.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Latanoprostene Bunod
Participants will instill 1 drop of latanoprostene bunod 0.024% topically into each eye QD in the evening for 14 days.
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
intraocular pressure (IOP)
Time Frame: Visit 3 (Day 14/15)
|
Efficacy of latanoprostene bunod dosed QD in reducing IOP from baseline.
IOP to be measured at multiple time points at visit 3.
|
Visit 3 (Day 14/15)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Blood levels following a single dose
Time Frame: 12 hours
|
The systemic pharmacokinetics (PK) of latanoprostene bunod, latanoprost acid, and Butanediol Mononitrate (BDMN) following a single dose of latanoprostene bunod.
blood samples to be collected pre dose, and multiple time points over a 12 hour period.
|
12 hours
|
Blood levels following multiple dosing
Time Frame: 14 days
|
The systemic PK of latanoprostene bunod, latanoprost acid and Butanediol Mononitrate (BDMN) following repeated QD dosing of latanoprostene bunod for 14 days.
Blood samples to be collected prior to day 14 dose and at multiple time points following dosing over a 12 hour period.
|
14 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2013
Primary Completion (Actual)
August 1, 2013
Study Completion (Actual)
October 1, 2013
Study Registration Dates
First Submitted
July 3, 2013
First Submitted That Met QC Criteria
July 10, 2013
First Posted (Estimate)
July 11, 2013
Study Record Updates
Last Update Posted (Actual)
May 15, 2018
Last Update Submitted That Met QC Criteria
May 9, 2018
Last Verified
May 1, 2018
More Information
Terms related to this study
Other Study ID Numbers
- 849
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Intraocular Pressure
-
Inonu UniversityCompletedIntraocular PressureTurkey
-
Vanderbilt University Medical CenterEnrolling by invitation
-
Medical University of ViennaCompletedIntraocular PressureAustria
-
Inonu UniversityCompletedIntraocular Pressure
-
The University of Texas Health Science Center,...Robert Cizik Eye ClinicCompletedIntraocular PressureUnited States
-
Isfahan University of Medical SciencesCompletedIntraocular PressureIran, Islamic Republic of
-
Tel-Aviv Sourasky Medical CenterUnknownIntraocular PressureIsrael
-
University of PittsburghRecruiting
Clinical Trials on Latanoprostene bunod
-
Bausch & Lomb IncorporatedCompletedOcular Hypertension | GlaucomaUnited States
-
Bausch & Lomb IncorporatedCompletedIntraocular PressureUnited States
-
Bausch & Lomb IncorporatedWithdrawn
-
University of California, San DiegoBausch & Lomb IncorporatedCompletedOAG - Open-Angle Glaucoma | OHT - Ocular HypertensionUnited States
-
Icahn School of Medicine at Mount SinaiCompleted